HomeCompareMRUS vs PM

MRUS vs PM: Dividend Comparison 2026

MRUS yields 2.22% · PM yields 3.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PM wins by $26.7K in total portfolio value
10 years
MRUS
MRUS
● Live price
2.22%
Share price
$90.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$23.0K
Annual income
$256.54
Full MRUS calculator →
PM
Philip Morris International
● Live price
3.49%
Share price
$164.83
Annual div
$5.76
5Y div CAGR
17.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$2,502.61
Full PM calculator →

Portfolio growth — MRUS vs PM

📍 PM pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMRUSPM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MRUS + PM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MRUS pays
PM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MRUS
Annual income on $10K today (after 15% tax)
$188.89/yr
After 10yr DRIP, annual income (after tax)
$218.06/yr
PM
Annual income on $10K today (after 15% tax)
$297.03/yr
After 10yr DRIP, annual income (after tax)
$2,127.22/yr
At 15% tax rate, PM beats the other by $1,909.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MRUS + PM for your $10,000?

MRUS: 50%PM: 50%
100% PM50/50100% MRUS
Portfolio after 10yr
$36.3K
Annual income
$1,379.58/yr
Blended yield
3.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PM right now

MRUS
Analyst Ratings
10
Buy
12
Hold
Consensus: Hold
Price Target
$97.00
+7.8% upside vs current
Range: $97.00 — $97.00
Altman Z
34.5
Piotroski
3/9
PM
Analyst Ratings
17
Buy
7
Hold
1
Sell
Consensus: Buy
Price Target
$194.30
+17.9% upside vs current
Range: $180.00 — $205.00
Altman Z
4.0
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MRUS buys
0
PM buys
0
No recent congressional trades found for MRUS or PM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMRUSPM
Forward yield2.22%3.49%
Annual dividend / share$2.00$5.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%17.2%
Portfolio after 10y$23.0K$49.6K
Annual income after 10y$256.54$2,502.61
Total dividends collected$2.4K$11.8K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy
Analyst price target$97.00$194.30

Year-by-year: MRUS vs PM ($10,000, DRIP)

YearMRUS PortfolioMRUS Income/yrPM PortfolioPM Income/yrGap
1← crossover$10,922$222.22$11,650$409.56$728.00PM
2$11,914$226.84$13,592$497.49$1.7KPM
3$12,979$231.24$15,882$605.21$2.9KPM
4$14,123$235.43$18,589$737.41$4.5KPM
5$15,351$239.43$21,794$899.94$6.4KPM
6$16,669$243.22$25,597$1,100.16$8.9KPM
7$18,082$246.82$30,118$1,347.30$12.0KPM
8$19,598$250.24$35,505$1,652.97$15.9KPM
9$21,224$253.47$41,940$2,031.88$20.7KPM
10$22,966$256.54$49,643$2,502.61$26.7KPM

MRUS vs PM: Complete Analysis 2026

MRUSStock

Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Full MRUS Calculator →

PMConsumer Staples

Philip Morris International Inc. operates as a tobacco company working to delivers a smoke-free future and evolving portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company's product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor, and oral nicotine products that are sold in markets outside the United States. The company offers its smoke-free products under the HEETS, HEETS Creations, HEETS Dimensions, HEETS Marlboro, HEETS FROM MARLBORO, Marlboro Dimensions, Marlboro HeatSticks, Parliament HeatSticks, and TEREA brands, as well as the KT&G-licensed brands, Fiit, and Miix. It also sells its products under the Marlboro, Parliament, Bond Street, Chesterfield, L&M, Lark, and Philip Morris brands. In addition, the company owns various cigarette brands, such as Dji Sam Soe, Sampoerna A, and Sampoerna U in Indonesia; and Fortune and Jackpot in the Philippines. The company sells its smoke-free products in 71 markets. Philip Morris International Inc. was incorporated in 1987 and is headquartered in New York, New York.

Full PM Calculator →
📬

Get this MRUS vs PM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MRUS vs SCHDMRUS vs JEPIMRUS vs OMRUS vs KOMRUS vs MAINMRUS vs MOMRUS vs BTIMRUS vs PEP

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.